Feature | September 11, 2017

TCT Announces 2017 Late-breaking Clinical Trial Presentations

TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.

September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected 12 late-breaking clinical trials and 16 first report Investigations that are guaranteed to impact patient care and future directions in cardiovascular technologies. 

 

 

Monday, October 30 - Main Arena I

 

Late-Breaking Clinical Trials 1

11 a.m.- noon

 

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Presenter is Holger Thiele.

 

EXCEL QOL: Quality of Life After PCI vs. CABG in Left Main Coronary Artery Disease. Presenter is Suzanne J. Baron.

 

DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs. Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions. Presenter is Shao-Liang Chen.

 

 

First Report Investigations 1

Noon - 1 p.m.

 

HREVS: A Randomized Trial of PCI vs. CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Presenter is Vladimir Ganyukov.

 

HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs. a Durable Polymer-Based DES in Patients With Coronary Artery Disease. Presenter is Shigeru Saito.

 

DARE: A Randomized Trial of a Drug-Eluting Balloon vs. a Metallic DES in Patients With Coronary Artery In-Stent Restenosis. Presenter is Jose P.S. Henriques.

 

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque. Presenter is Kiyoshi Hibi. 

 

 

 

Tuesday, October 31, 2017 - Main Arena II

 

Late-Breaking Clinical Trials 2: Co-sponsored by the Lancet

11 a.m. - Noon

 

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs. a Metallic DES in Patients With Coronary Artery Disease. Presented by Gregg W. Stone.

 

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Stephen G. Ellis.

 

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis. Presented by David J. Cohen.

 

 

 

First Report Investigations 2

Noon - 1:07 p.m.

 

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Bernard R. Chevalier.

 

CrossBoss First: A Randomized Trial of Antegrade Dissection and Re-entry vs Standard Wire Escalation for Crossing Coronary Artery Chronic Total Occlusions. Presented by Emmanouil S. Brilakis.

 

REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions. Presented by Kambis Mashayekhi.

 

FAVOR II China: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio in Patients With Coronary Artery Disease. Presented by Bo Xu.

 

FAVOR II Europe Japan: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio in Patients With Coronary Artery Disease. Presented by Jelmer Westra.

 

 

 

 

Wednesday, November 1, 2017 - Main Arena III

 

Late-Breaking Clinical Trial 3: Co-sponsored by the Journal of the American Medical Association

11 a.m. - Noon

 

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs. a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years. Presented by Olivier Varenne.

 

DAPT STEMI: A Randomized Trial of 6-Month vs. 12-Month DAPT After DES Implantation in STEMI. Presented by Elvin Kedhi.

 

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS. Presented by Harry Suryapranata.

 

 

 

First Report Investigations 3

Noon - 1:03 p.m.

 

MITRAL: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings. Presented by Mayra Guerrero.

 

INTREPID: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by Paul Sorajja.

 

TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by David W.M. Muller.

 

TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair in Patients With Severe Primary Mitral Regurgitation. Presented by James S. Gammie.

 

MAVERIC: 6-Month Outcomes of Transcatheter MV Repair in Patients With Severe Secondary Mitral Regurgitation. Presented by Stephen G. Worthley.

 

 

 

Thursday, November 2, 2017 - Main Arena IV

 

Late-Breaking Clinical Trials 4

9:30 a.m. - 10:30 a.m.

 

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure (LAA) vs. Medical Therapy in Patients With Non-Valvular Atrial Fibrillation. Presented by Vivek Y. Reddy.

 

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease. Presented by Rasha Al-Lamee.

 

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease. Presented by William F. Fearon.

 

 

 

First Report Investigations 4

10:30 a.m. - 11 a.m.

 

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Georg Nickenig.

 

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Susheel K. Kodali.

 

For more information: www.crf.org/tct/agenda/2017-late-breaking-trials-and-first-report-investigations

 

Links to Other Late-breaking Trials: 

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Overlay Init